Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Blood

Volumn 124, Issue 4, 2014, Pages 503-510

  Treon, Steven P ^a   Tripsas, Christina K ^a   Meid, Kirsten ^a   Kanan, Sandra ^a   Sheehy, Patricia ^a   Chuma, Stacey ^a   Xu, Lian ^a   Cao, Yang ^a   Yang, Guang ^a   Liu, Xia ^a   Patterson, Christopher J ^a   Warren, Diane ^a   Hunter, Zachary R ^a   Turnbull, Barry ^b   Ghobrial, Irene M ^a   Castillo, Jorge J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BioBridges Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARFILZOMIB; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; EVEROLIMUS; FAMOTIDINE; IBRUTINIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MYELOID DIFFERENTIATION FACTOR 88; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HERPES ZOSTER; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOKALEMIA; INJECTION SITE REACTION; INSOMNIA; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; SOMATIC MUTATION; THERAPY DELAY; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; OLIGOPEPTIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84904916820     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-566273     Document Type: Article

References (31)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115. (Pubitemid 36506291)
2. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Bortezomib in Waldenström's macroglobulinemia. Haematologica. 2005;90: 1655-1658.
3. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007; 13(11):3320-3325. (Pubitemid 46944918)
4. Chen CI, Kouroukis CT, White D, et al; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(12):1570-1575. (Pubitemid 46733084)
5. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23): 3830-3835.
6. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. J Clin Oncol. 2010;28(8):1422-1428.
7. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010;85(9): 670-674.
8. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol. 2010;151(4):346-353.
9. Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenström macroglobulinaemia. Br J Haematol. 2011;154(2):223-228.
10. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013; 122(19):3276-3282.
11. Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987;37(9):1506-1514. (Pubitemid 17132332)
12. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114(12): 2375-2385.
13. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11): 1753-1761.
14. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011; 17(9):2734-2743.
15. Sacco A, Aujay M, Morgan B, et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenström's Macroglobulinemia. Clin Cancer Res. 2011;17(7): 1753-1764.
16. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstöm's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2013;123(11) 1637-1646.
17. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood. 2014;123(18):2791-2796.
18. Treon SP, Tripsas C, Yang G, et al. A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenström's macroglobulinemia. Blood. 2013;122(21):251.
19. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30(2): 116-120. (Pubitemid 36506292)
20. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009;113(23): 5927-5937.
21. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia. J Clin Oncol. 2009;27(1): 120-126.
22. Owen RG, Kyle RA, Stone MJ, et al; VIth International Workshop on Waldenström macroglobulinaemia. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171-176.
23. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113(18): 4163-4170.
24. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11): 2051-2058.
25. Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance [published online ahead of print February 10, 2014]. Leukemia.
26. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344-3349. (Pubitemid 47325621)
27. Treon SP, Branagan AR, Ioakimidis L, et al. Longterm outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009; 113(16):3673-3678.
28. Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012;128(4):244-247.
29. Laubach JP, San Miguel JF, Sonneveld P, et al. Quantifying the risk of heart failure associated with proteasome inhibition: A retrospective analysis of heart failure reported in phase 2 and phase 3 studies of bortezomib in multiple myeloma [abstract]. Blood. 2013122:3187; published ahead of print December 6, 2013.
30. Hunter ZR, Manning RJ, Hanzis C, et al. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica. 2010;95(3): 470-475.
31. Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenström Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154(3):357-362.